Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study

  • Martina Theresa KralingerEmail author
  • Ulrike Stolba
  • Michaela Velikay
  • Stefan Egger
  • Susanne Binder
  • Andreas Wedrich
  • Anton Haas
  • Jean-Marie Parel
  • Gerhard Franz Kieselbach
Medical Ophthalmology



The safety and efficacy of a new surgical method of intravitreal tamponade using silicone oil suspended with aspirin (acetylsalicylic acid) was investigated for the treatment of proliferative vitreoretinopathy.


The study was designed as a prospective, randomized, controlled, double-blind multicenter study. A total of 29 patients were included; 15 patients were treated with the silicone oil suspended with aspirin, and 14 patients represented the control group receiving only silicone oil. A standard three-port pars plana vitrectomy was performed in 29 eyes of 29 patients. In cases in which the natural lens was present, simultaneous phacoemulsification was required. The control group received as standard therapy a vitreous tamponade with pure 5000 mPas silicone oil and the treatment group received silicone oil containing 0.2 mg/ml aspirin (AS SiO). At 6 months after surgery, the tamponade was removed from all eyes. The main outcome measure was the incidence of retinal redetachment requiring reoperation. Secondary outcome measures were visual acuity and ophthalmic examination results.


The rate of redetachment, defined as the primary outcome parameter, was the same for both groups. The AS SiO was well tolerated and remained clear during the 6-month study period. Clinical examination revealed no signs of local or systemic adverse effects. The visual acuities were well matched before inclusion in the study and there were no significant differences during the follow-up period and in the final visual outcome between the two groups.


Aspirin delivery by intravitreal silicone oil in the human eye is safe and also may provide a delivery vehicle for other antiproliferative agents to the posterior pole.


Acetyl-salicylic acid Silicone oil Proliferative vitreoretinopathy 



We are very grateful to Dr. Dresp from Bausch&Lomb for financing the production of the AS SiO at Pharm Pur. We also thank Prof. Hanno Ulmer for the statistical analyses. This project was supported by the Adele Rabensteiner Stiftung of the Austrian Society of Ophthalmology.


  1. 1.
    Asiyo-Vogel MN, El-Hifnawi ES, Bopp S, Laqua H (1998) The vascular component of proliferative vitreoretinopathy membranes: an immunohistochemical and ultrastructural study. Retina 18:56–61CrossRefPubMedGoogle Scholar
  2. 2.
    Claes C, Freeman HM, Tolentino FI (1988) PVR: an overview. In: Freeman HM, Tolentino FI (eds) Proliferative vitreoretinopathy. Springer, Berlin Heidelberg New York , pp 3–11Google Scholar
  3. 3.
    Machemer R (1978) Pathogenesis and classification of massive periretinal proliferation. Br J Ophthalmol 62:737–740CrossRefPubMedGoogle Scholar
  4. 4.
    Hilton GF (1974) Subretinal pigment migration: effects of cryosurgical reattachment. Arch Ophthalmol 91:445PubMedGoogle Scholar
  5. 5.
    Lean J, Azen SP, Lopez PF, Qian D, Lai MY, McCuen B (1996) The prognostic utility of the Silicone Study Classification System. Silicone Study Report 9. Silicone Study Group. Arch. Ophthalmol 114:286–292Google Scholar
  6. 6.
    Rachal WF, Burton TC (1979) Changing concepts of failure after retinal detachment surgery. Arch Ophthalmol 97:480–483PubMedGoogle Scholar
  7. 7.
    Silicone Study Group (1985) Proliferative vitreoretinopathy. Am J Ophthalmology 99:593–595Google Scholar
  8. 8.
    Brourman ND, Blumenkranz MS, Cox MS, Trese MT (1989) Silicone oil for the treatment of severe proliferative diabetic retinopathy. Ophthalmology 96:759–764PubMedGoogle Scholar
  9. 9.
    McCuen BW 2nd, Azen SP, Stern W, Lai MY, Lean JS, Linton KL, Ryan SJ (1993) Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 3. Retina 13:279–284CrossRefPubMedGoogle Scholar
  10. 10.
    Silicone Study Group (1992) Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol 110:770–779Google Scholar
  11. 11.
    Silicone Study Group (1992) Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol 110:780–790Google Scholar
  12. 12.
    Parel J-M, Villain F (1994) Silicone oils: physicochemical properties. In: Ryan SJ (ed) Retina, vol 3, 2nd edn. Mosby, St. Louis, pp 2131–2149Google Scholar
  13. 13.
    Kralinger MT, Kieselbach GF, Voigt M, Parel J-M (2001) Slow release of acetylsalicylic acid by intravitreal silicone oil. Retina 21(5):513–520CrossRefPubMedGoogle Scholar
  14. 14.
    Kralinger MT, Hamasaki D, Kieselbach FG, Voigt M, Parel J-M (2001) Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of safety by ERG and histology. Graefe’s Arch Clin Exp Ophtalmol 239:208–216CrossRefGoogle Scholar
  15. 15.
    Valeri P, Romanelli L, De Paolis L, Martinelli B (1988) Ocular distribution of aspirin and salicylate following systematic administration of aspirin to rabbits. J Pharm Pharmacol 40:823–824PubMedGoogle Scholar
  16. 16.
    Valeri P, Romanelli L, Martinelli B, Guglielmotti A, Catanese B (1989) Time-course of aspirin and salicylate in ocular tissues of rabbits. Lens Eye Toxic Res 6:465–475PubMedGoogle Scholar
  17. 17.
    Voigt M, Kralinger M, Kieselbach G, Chapon P, Anagnoste S, Hayden B, Parel J-M (2002) Ocular aspirin distribution: a comparison of intravenous, topical, and Coulomb-controlled iontophoresis administration. Invest Ophthalmol Vis Sci 43(10):3299–3306PubMedGoogle Scholar
  18. 18.
    Kralinger MT, Voigt M, Kieselbach GF, Hamasaki D, Hayden BC, Parel J-M (2003) Ocular delivery of acetylsalicylic acid by repetitive Coulomb-controlled iontophoresis. Ophthalmic Research 35:102–110CrossRefPubMedGoogle Scholar
  19. 19.
    Kaehler C, Kieselbach G, Reinisch N, Troger J, Göttinger W, Wiedermann CJ (1994) Fibroblast growth-promoting activity in proliferative vitreoretinopathy: antagonism by AS. Eur J Pharmacol 262:261–269CrossRefGoogle Scholar
  20. 20.
    Chan IM, Tolentino FI, Refojo MF, Fournier G, Albert DM (1984) Vitreous substitute: experimental studies and review. Retina 4:51–59CrossRefPubMedGoogle Scholar
  21. 21.
    Miyamoto K, Refojo MF, Tolentino FI, Fournier GA, Albert DM (1984) Perfluoroether liquid as a long term vitreous substitute: an experimental study. Retina 4:264–268CrossRefPubMedGoogle Scholar
  22. 22.
    Arroyo MH, Refojo MF, Araiz JJ, Tolentino FL, Cajita VN, Elner VM (1993) Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy. Retina 13:245–250CrossRefPubMedGoogle Scholar
  23. 23.
    Chung H, Tolentino FI, Cajita VN, Ueno N, Refojo MF (1988) BCNU in silicone oil in proliferative vitreoretinopathy: solubility, stability (in vitro and in vivo), and antiproliferative (in vitro) studies. Curr Eye Res 7:1199–1206CrossRefPubMedGoogle Scholar
  24. 24.
    Larrosa JM, Veloso AA Jr, Leong FL, Refojo MF (1997) Antiproliferative effect of intravitreal alpha-tocopherol and alpha-tocopheryl-acid-succinate in a rabbit model of PVR. Eye Curr Res 16:1030–1035CrossRefGoogle Scholar
  25. 25.
    Nakagawa M, Refojo MF, Marin JF, Doi M, Tolentino Fl (1995) Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 36:2388–2395Google Scholar
  26. 26.
    Araiz JJ, Refojo MF, Arroyo MH, Leong FL, Albert DM, Tolentino FL (1993) Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 34:522–530PubMedGoogle Scholar
  27. 27.
    Weller M, Wiedemann P, Heimann K (1990) Proliferative vitreoretinopathy-is it anything more than wound healing at the wrong place? Int Ophthalmol 14(2):105–117CrossRefPubMedGoogle Scholar
  28. 28.
    Esser P, Tervooren D, Heimann K, Kociok N, Bartz-Schmidt KU, Walter P, Weller M (1998) Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 39:164–170PubMedGoogle Scholar
  29. 29.
    Hegazy HM, Peyman GA, Liang C, Unal MH, Molinari LC, Kazi AA (1998–1999) Use of perfluorocarbon liquids, silicone oil, and 5-fluorouracil in the management of experimental PVR. Int Ophthalmol 22(4):239–246Google Scholar
  30. 30.
    Wiedemann P, Hilgers RD, Bauer P, Heimann K (1998) Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol 126(4):550–559CrossRefPubMedGoogle Scholar
  31. 31.
    Shinohara K, Tanaka M, Sakuma T, Kobayashi Y (2003) Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging 34:299–305PubMedGoogle Scholar
  32. 32.
    Herrero-Vanrell R, Refojo MF (2001) Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev 52:5–16CrossRefPubMedGoogle Scholar
  33. 33.
    Yasukawa T, Kimura H, Tabata Y, Ogura Y (2001) Biodegradable scleral plugs for vitreoretinal drug delivery. Adv Drug Deliv Rev 52:25–36CrossRefPubMedGoogle Scholar
  34. 34.
    Vote B, Wheen L, Cluroe A, Teoh H, McGeorge A (2003) Further evidence for proinflammatory nature of perfluorohexyloctane in the eye. Clin Experiment Ophthalmol 31(5):408–414CrossRefPubMedGoogle Scholar
  35. 35.
    Sandner D, Herbrig E, Engelmann K (2007) High-density silicone oil (Densiron) as a primary intraocular tamponade: 12-month follow up. Graefes Arch Clin Exp Ophthalmol 245(8):1097–1105CrossRefPubMedGoogle Scholar
  36. 36.
    Mackiewicz J, Muehling B, Hiebl W, Meinert H, Maaijwee K, Kociok N, Lüke C, Zagorski Z, Kirchhof B, Joussen AM (2007) In vivo retinal tolerance of various heavy silicone oils. Invest Ophthalmol Vis Sci 48(4):1873–1883CrossRefPubMedGoogle Scholar
  37. 37.
    Tognetto D, Minutola D, Sanguinetti G, Ravalico G (2005) Anatomical and functional outcomes after heavy silicone oil tamponade in vitreoretinal surgery for complicated retinal detachment: a pilot study. Ophthalmology 112(9):1574CrossRefPubMedGoogle Scholar
  38. 38.
    Analgesics and antipyretics. In: McEvoy GE, Litvak K, Walsh O (eds) American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Hospital Pharmacists Inc., 1989;962–966Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Martina Theresa Kralinger
    • 1
    • 8
    Email author
  • Ulrike Stolba
    • 2
  • Michaela Velikay
    • 3
  • Stefan Egger
    • 4
  • Susanne Binder
    • 2
  • Andreas Wedrich
    • 3
  • Anton Haas
    • 3
  • Jean-Marie Parel
    • 5
    • 6
    • 7
  • Gerhard Franz Kieselbach
    • 1
  1. 1.Department of OphthalmologyInnsbruck Medical UniversityInnsbruckAustria
  2. 2.Department of OphthalmologyKA RudolfstiftungViennaAustria
  3. 3.Department of OphthalmologyGraz Medical UniversityGrazAustria
  4. 4.Department of OphthalmologySalzburg Medical UniversitySalzburgAustria
  5. 5.Ophthalmic Biophysics Center, Bascom Palmer Eye InstituteUniversity of Miami, School of MedicineMiamiUSA
  6. 6.CHU Sart-Tilman, Department of OphthalmologyUniversity of LiègeLiègeBelgium
  7. 7.University of ParisHopital de l’Hotel-DieuParisFrance
  8. 8.Department of Ophthalmology and OptometryMedical University InnsbruckInnsbruckAustria

Personalised recommendations